In the present study, we provided evidence from cells, xenograft tumors, and human tumors to demonstrate that ERK activation by PXN promoted tumor aggressiveness and led to poor patient outcome in colorectal cancer and that this promotion occurs via increased pBcl-2-S87-mediated MMP2 expression. The gene discussed is MMP2; the disease is colorectal cancer.